Message From CEO


Welcome to the Diurnal website and allow me to introduce our company. Diurnal’s mission is to develop new treatments and to deliver the best possible health outcomes for chronic endocrine conditions.

At the heart of everything we do at Diurnal is the patient. Diurnal’s approach has been the focussed goal of developing products that can address the unmet patient and clinical needs in endocrinology. So how do we do this?

The Diurnal team has significant expertise in understanding and creating pharmaceutical products, taking these products through the clinical and regulatory process through to commercialisation. In 2018 we successfully launched our first product in Europe for the paediatric form of the rare disease adrenal insufficiency. We have since followed up on our first breakthrough by securing further approvals in Australia, Israel and the US. We intend to make our products available as widely as possible across the globe, to provide valuable treatment options to patients, by either making products available directly through our own sales force or with partners through marketing and distribution agreements such as in Turkey, Switzerland and New Zealand or through licensing agreements as in China, Hong Kong, Taiwan and Macau. I am delighted to inform you that we continue to make year-on-year progress across several continents with further launches to follow in 2021.

May 2021 heralded the expansion of our product portfolio when the European Commission granted approval for our second product – a treatment of the rare disease congenital adrenal hyperplasia – for the European Economic Area (including Northern Ireland) (EEA). This was closely followed by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) who granted approval for Great Britain (England, Wales and Scotland) in July 2021. To facilitate timely commercial availability, Diurnal has already commenced market access activities in its target European territories, with the first commercial launch anticipated in Q3 2021.

Beyond these lead programmes, we plan to build out our endocrine product pipeline so that we can achieve our goal of becoming one of the world’s leading specialty endocrinology companies. I hope that you read further to understand the substantial work that we are carrying out in the field of endocrinology.

Martin Whitaker

Chief Executive Officer

Diurnal Group plc (Company Number: 09846650) is registered in England & Wales. Registered office: Cardiff Medicentre, Heath Park, Cardiff CF14 4UJ, UK.